



# MEDICAL DIAGNOSTIC LABORATORIES L.L.C.

2439 KUSER ROAD

HAMILTON, NJ 08690-3303

TL: 609-570-1000 FX: 609-570-1050 TF: 877-269-0090

www.mdlab.com

**Final**

**MDL#: 2699936**

## Test Results

**Physician Copy**

<b>Patient Information:</b> <b>SSN: XXX-XX-2333</b> <b>DOB: 10/23/1982</b>  <b>DOE, JANE</b> 123 SMITH DRIVE FORT WORTH, TX 76123  <b>Home: (817) 721-0643</b>	<b>Ordering Physician/Lab:</b>  <b>JOHN DOE MD</b> <b>JOHN DOE, MD</b> 201 ANY STREET YOUNG AMERICA, MN 55555  <b>Tel: 555-555-5551</b> <b>Fax: 555-555-5552</b>	<b>NPI: 1234567890</b>
---	--	------------------------

Patient ID: **1354**

Date Processed: **3/30/2010**

Date Reported: **4/1/2010**

Test	Specimen	Date Collected Comment	Results		Reference/Units/Comments
			Normal	Abnormal	
<b>Chlamydia trachomatis by Real-Time PCR</b>  105 <i>Verified 3/31/2010</i> <i>Swab - 1</i>	*	3/29/2010 Endocerv	Negative		
<b>Trichomonas vaginalis by Real-Time PCR</b>  111 <i>Verified 3/31/2010</i> <i>Swab - 1</i>	*	3/29/2010 Endocerv	Negative		
<b>Neisseria gonorrhoeae by Real-Time PCR (Reflex to ciprofloxacin Resistance by Pyrosequencing)</b>  145 <i>Verified 3/31/2010</i> <i>Swab - 1</i>	*	3/29/2010 Endocerv	Negative		
<b>HPV Type-Detect 2.0 by Bio-Plex Analysis</b>  152 <i>Verified 4/1/2010</i> <i>Swab - 1</i>	*	3/29/2010 Endocerv		Detected	Subtypes HPV: 16 (HR). See explanation below.

\*This test was developed and its performance characteristics determined by Medical Diagnostic Laboratories, L.L.C. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

**HPV-16 high-risk**

is the most common type among cervical cancer cases. It accounts for about half of all cases of squamous cell carcinoma worldwide. It is also the second most prevalent type in patients with cervical adenocarcinomas. The presence of HPV-16 places a woman at 38 times the risk for the development of cervical cancer compared to those who are HPV negative. In accordance with ACOG recommendations, women with a negative cytology screen who test positive for HPV-16 should have another cytology screen, and HPV test in 6 to 12 months. A vaccine that prevents persistent infection with this virus is now commercially available.

A positive result is provided for bacteria, virus, and/or fungal species when PCR amplification (real-time PCR), sequence information (Pyrosequencing), and/or signal detection (Bio-Plex Analysis) occurs above cut-off levels established by the laboratory. Pertinent reference intervals for the tests reported above are available from the laboratory upon request.

end of report

View: M

Mail:	Yes	USPS
	All	Yes

Fax:	Yes	Manual
	All	No

*Dante A. Ragasa*  
**Dante A. Ragasa M.D.**  
 Medical Director